CAR T-cell therapy in pediatric oncology: From leukemia to emerging promise in Wilms tumor and solid malignancies

In brief

This article explores CAR T-cell therapy's evolution in pediatric cancer treatment, from its groundbreaking success in acute lymphoblastic leukemia to its expanding application in solid tumors including Wilms tumor. The piece traces the technology's development from first-generation CARs in the early 1990s through FDA approval and clinical implementation, highlighting its role as a personalized immunotherapeutic approach in childhood malignancies.

• CAR T-cell therapy genetically modifies patient T cells to target cancer, providing personalized treatment in pediatric oncology.
• Second-generation CARs (early 2000s) showed enhanced efficacy over first-generation designs from 1989-1993.
• FDA-approved CAR T achieved first pediatric complete remission in ALL in 2013, establishing proof of concept.
• Technology evolved from 1980s immunotherapy research to clinical application over three decades of development.
• CAR T shows emerging promise beyond leukemia, with potential applications in Wilms tumor and other solid malignancies.

Written by the GCMD Library team from the article.